Masayuki Hiramatsu

ORCID: 0000-0003-3723-310X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neuroscience and Neuropharmacology Research
  • Neuropeptides and Animal Physiology
  • Receptor Mechanisms and Signaling
  • Pharmacological Receptor Mechanisms and Effects
  • Nicotinic Acetylcholine Receptors Study
  • Neurotransmitter Receptor Influence on Behavior
  • Neuroendocrine regulation and behavior
  • Stress Responses and Cortisol
  • Tryptophan and brain disorders
  • Heme Oxygenase-1 and Carbon Monoxide
  • Cholinesterase and Neurodegenerative Diseases
  • Psychedelics and Drug Studies
  • Chemical synthesis and alkaloids
  • Memory and Neural Mechanisms
  • Pain Mechanisms and Treatments
  • Cannabis and Cannabinoid Research
  • Birth, Development, and Health
  • Biochemical effects in animals
  • Alzheimer's disease research and treatments
  • Metabolism and Genetic Disorders
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Diet and metabolism studies
  • Pharmacogenetics and Drug Metabolism
  • Silicon and Solar Cell Technologies
  • Analytical Chemistry and Chromatography

Meijo University
2016-2025

Nagoya University
1983-2020

Japanese Society for Dialysis Therapy
2019

National Pension Service
2019

Okayama Saiseikai General Hospital
2016-2017

Osaka Medical and Pharmaceutical University
2008-2009

Nihon University
2002

Tohoku University of Community Service and Science
2001

Pharmac
1999

Osaka Prefecture University
1993-1994

The in vitro conversion of (+)-3,4-methylenedioxymethamphetamine and (-)-3,4-methylenedioxymethamphetamine to the corresponding catecholamine, 3,4-dihydroxymethamphetamine (N-methyl-alpha-methyldopamine), by rat liver microsomes was examined. Metabolite formation monitored after short-term incubations using high-performance liquid chromatography-electrochemical detection determine concentrations catecholamine. N-methyl-alpha-methyldopamine exhibited enantioselectivity levels were...

10.1016/s0022-3565(25)12653-0 article EN Journal of Pharmacology and Experimental Therapeutics 1990-08-01

Accumulated evidence suggests that oxidative stress is involved in amyloid beta (Abeta)-induced cognitive dysfunction. Silibinin (silybin), a flavonoid derived from the herb milk thistle (Silybum marianum), has been shown to have antioxidative properties; however, it remains unclear whether silibinin improves Abeta-induced neurotoxicity. In present study, we examined effect of on memory impairment and accumulation induced by Abeta(25-35) mice.Aggregated (3 nmol) was intracerebroventricularly...

10.1111/j.1476-5381.2009.00295.x article EN British Journal of Pharmacology 2009-06-22

BACKGROUND AND PURPOSE Cilostazol may be effective in dementia associated with a cerebral ischaemia. In this study, we examined whether it exerts beneficial effects on learning and/or memory impairment induced by Aβ 25‐35 mice, and compared its those of aspirin. EXPERIMENTAL APPROACH (9 nmol) was administered to mice i.c.v. Learning behaviour were evaluated measuring spontaneous alternation Y‐maze step‐down type passive avoidance test, the 5th 8th days after injection respectively. Levels...

10.1111/j.1476-5381.2010.01014.x article EN British Journal of Pharmacology 2010-09-03

In Alzheimer's disease (AD), the deposition of amyloid peptides is invariably associated with oxidative stress and inflammatory responses. Silibinin (silybin), a flavonoid derived from herb milk thistle, has potent anti-inflammatory antioxidant activities. However, it remains unclear whether silibinin improves β (Aβ) peptide-induced neurotoxicity. this study, we examined effect on fear-conditioning memory deficits, response, induced by intracerebroventricular injection Aβ...

10.1124/jpet.109.155069 article EN Journal of Pharmacology and Experimental Therapeutics 2009-07-28

Betaine (glycine betaine or trimethylglycine) plays important roles as an osmolyte and a methyl donor in animals. While is reported to suppress expression of proinflammatory molecules reduce oxidative stress aged rat kidney, the effects on central nervous system are not well known. In this study, we investigated lipopolysaccharide (LPS)-induced memory impairment mRNA levels molecules, glial markers, GABA transporter 2 (GAT2), betaine/GABA transporter.Mice were continuously treated with for...

10.1186/1742-2094-8-153 article EN cc-by Journal of Neuroinflammation 2011-11-04

Abstract Background Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through the serotonin 5-HT2A receptor (5-HT2A). Recent studies have revealed that serotonergic therapeutic potential for neuropsychiatric disorders, including major depressive anxiety-related disorders. Aims & Objectives The involvement of in mediating effects remains unclear. In this study, we analyzed role occurrence anxiolytic- antidepressant-like...

10.1093/ijnp/pyae059.584 article EN cc-by-nc The International Journal of Neuropsychopharmacology 2025-02-01

The in vivo N-demethylation of (+) and (-)3,4-methylenedioxymethamphetamine (MDMA) to 3,4-methylenedioxyamphetamine (MDA) was determined the pharmacokinetic relationship between two compounds calculated. levels MDA formed after iv administration (+)MDMA male rats were about 3 times greater than those for (-)MDMA, although plasma parent drugs comparable. Plasma concentrations lower phenobarbital-pretreated rats, but SKF 525-A pretreatment, at dose used, had minimal effects. In liver microsome...

10.1016/s0090-9556(25)08631-3 article EN Drug Metabolism and Disposition 1990-09-01

In the majority of schizophrenia patients, chronic atypical antipsychotic administration produces a significant reduction in or even complete remission psychotic symptoms such as hallucinations and delusions. However, these drugs are not effective improving cognitive emotional deficits patients with schizophrenia. Atypical have high affinity for dopamine D2 receptor, modest serotonin 5-HT2A receptor. The thought to involve neural networks beyond classical dopaminergic mesolimbic pathway,...

10.3389/fncel.2020.00285 article EN cc-by Frontiers in Cellular Neuroscience 2020-09-02
Coming Soon ...